This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAkumin (AKUM.Q) 주식 개요Akumin Inc. provides outpatient diagnostic imaging services in the United States. 자세히 보기AKUM.Q 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성2/6배당0/6위험 분석지난 5년간 매년 수익이 72.8% 감소했습니다.마이너스 주주 지분의미 있는 시가총액이 없습니다($34M)모든 위험 점검 보기AKUM.Q Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.3898.6% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-262m3b2016201920222025202620282031Revenue US$3.3bEarnings US$241.4mAdvancedSet Fair ValueView all narrativesAkumin Inc. 경쟁사Mobile-health Network SolutionsSymbol: NasdaqCM:MNDRMarket cap: US$3.2mConcord Medical Services HoldingsSymbol: NYSE:CCMMarket cap: US$21.4mP3 Health PartnersSymbol: NasdaqCM:PIIIMarket cap: US$88.2mAmerican Shared Hospital ServicesSymbol: NYSEAM:AMSMarket cap: US$9.7m가격 이력 및 성과Akumin 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.3852주 최고가US$1.3052주 최저가US$0.12베타0.151개월 변동9.16%3개월 변동14.02%1년 변동-67.67%3년 변동-88.39%5년 변동-89.92%IPO 이후 변동-90.42%최근 뉴스 및 업데이트공시 • Dec 02Akumin Unveils World-First Akumin AXIS Relocatable Imaging Center with latest Siemens' PET-CT at RSNAAkumin Inc. unveiled the world's first Akumin AXIS Relocatable & Expandable Outpatient Center at the Radiological Society of North America (RSNA) meeting. This groundbreaking innovation, which is engineered to meet critical radiology and oncology requirements, was launched with a ribbon-cutting ceremony at the Akumin Booth #6158 (North Hall) on Sunday. Designed and built in the United States, Akumin AXIS is a fully equipped Outpatient Imaging or Radiation Therapy Center supporting many modalities, including PET-CTs, Linear Accelerators, and MRIs (in-progress). The spacious layout enables high-volume scanning, with 3 uptake rooms for tracer and theranostic infusions, i.e. radioligand therapies. The first unit unveiled on Sunday features Siemens Healthineers' Digital Biograph Trinion PET-CT scanner, which sets a benchmark for precision imaging and clinical outcomes. The Biograph Trinion PET-CT's unique, air-cooled design makes this solution optimal for the Akumin AXIS solution. The unveiling has sparked tremendous interest among RSNA attendees, since Akumin AXIS solves 3 key challenges faced by health systems today: large capital costs, construction time/delays, and staffing shortages. Attendees have been impressed by how Akumin AXIS enables an efficient expansion of services, improving access to high-quality care.공시 • Feb 09+ 1 more updateAkumin Appoints Chandra Westergaard as General CounselAkumin announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. Chandra Westergaard joins Akumin from Envision Healthcare, where she most recently served as Vice President, Associate General Counsel, and Chief Litigation Counsel. Previously, she served as a Partner at Norton Rose Fulbright and Senior Counsel at Perkins Coie. Chandra also spent more than six years at DaVita as Assistant General Counsel, leading the Office of Special Counsel, and began her legal career in the healthcare group at Crowell & Moring. She received a Juris Doctorate from the Duke University School of Law and a Bachelor of Arts in Philosophy from McDaniel College.공시 • Feb 08Akumin Files Form 15Akumin Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.공시 • Dec 30Akumin Inc. Announces Chief Financial Officer ChangesAkumin Inc. announced that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and middle-market companies. Leveraging his financial and operational expertise, Ronald guides companies in making data-driven decisions that support restructuring strategies, financial forecasts, and cost reduction programs. Ronald has an MBA from the University of Michigan'sRoss School of Business and is a former Certified Treasury Professional.공시 • Nov 18Nasdaq to Delist the Securities of AkuminNasdaq announced that it will delist the securities of Akumin Inc. The company’s securities were suspended on October 26, 2023, and have not traded on Nasdaq since that time.공시 • Nov 16Akumin Inc. announced delayed 10-Q filingOn 11/14/2023, Akumin Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.더 많은 업데이트 보기Recent updates공시 • Dec 02Akumin Unveils World-First Akumin AXIS Relocatable Imaging Center with latest Siemens' PET-CT at RSNAAkumin Inc. unveiled the world's first Akumin AXIS Relocatable & Expandable Outpatient Center at the Radiological Society of North America (RSNA) meeting. This groundbreaking innovation, which is engineered to meet critical radiology and oncology requirements, was launched with a ribbon-cutting ceremony at the Akumin Booth #6158 (North Hall) on Sunday. Designed and built in the United States, Akumin AXIS is a fully equipped Outpatient Imaging or Radiation Therapy Center supporting many modalities, including PET-CTs, Linear Accelerators, and MRIs (in-progress). The spacious layout enables high-volume scanning, with 3 uptake rooms for tracer and theranostic infusions, i.e. radioligand therapies. The first unit unveiled on Sunday features Siemens Healthineers' Digital Biograph Trinion PET-CT scanner, which sets a benchmark for precision imaging and clinical outcomes. The Biograph Trinion PET-CT's unique, air-cooled design makes this solution optimal for the Akumin AXIS solution. The unveiling has sparked tremendous interest among RSNA attendees, since Akumin AXIS solves 3 key challenges faced by health systems today: large capital costs, construction time/delays, and staffing shortages. Attendees have been impressed by how Akumin AXIS enables an efficient expansion of services, improving access to high-quality care.공시 • Feb 09+ 1 more updateAkumin Appoints Chandra Westergaard as General CounselAkumin announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. Chandra Westergaard joins Akumin from Envision Healthcare, where she most recently served as Vice President, Associate General Counsel, and Chief Litigation Counsel. Previously, she served as a Partner at Norton Rose Fulbright and Senior Counsel at Perkins Coie. Chandra also spent more than six years at DaVita as Assistant General Counsel, leading the Office of Special Counsel, and began her legal career in the healthcare group at Crowell & Moring. She received a Juris Doctorate from the Duke University School of Law and a Bachelor of Arts in Philosophy from McDaniel College.공시 • Feb 08Akumin Files Form 15Akumin Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.공시 • Dec 30Akumin Inc. Announces Chief Financial Officer ChangesAkumin Inc. announced that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and middle-market companies. Leveraging his financial and operational expertise, Ronald guides companies in making data-driven decisions that support restructuring strategies, financial forecasts, and cost reduction programs. Ronald has an MBA from the University of Michigan'sRoss School of Business and is a former Certified Treasury Professional.공시 • Nov 18Nasdaq to Delist the Securities of AkuminNasdaq announced that it will delist the securities of Akumin Inc. The company’s securities were suspended on October 26, 2023, and have not traded on Nasdaq since that time.공시 • Nov 16Akumin Inc. announced delayed 10-Q filingOn 11/14/2023, Akumin Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Oct 27Akumin Inc.(OTCPK:AKUM.Q) dropped from NASDAQ Composite IndexAkumin Inc. has been removed from NASDAQ Composite Index .공시 • Oct 26Akumin Inc.(NasdaqCM:AKU) dropped from S&P TMI IndexAkumin Inc.(NasdaqCM:AKU) dropped from S&P TMI Index공시 • Oct 24Akumin Inc. Filed for BankruptcyAkumin Inc., along with its 55 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on October 22, 2023. The debtor listed its assets in the range of $100 million to $500 million and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Victoria Nicole Argeroplos, Beau Butler, Matthew D Cavenaugh, John Machir Stull and Jennifer F Wertz of Jackson Walker LLP and Dorsey & Whitney LLP as its legal counsels and Stikeman Elliott LLP as special Canadian counsel. The debtor also hired Leerink Partners as its investment banker, AlixPartners, LLP as its financial advisor and Epiq Corporate Restructuring LLC as noticing and claims agent. Ronald J. Bienias of AlixPartners, LLP acted as chief restructuring officer.공시 • Oct 22+ 1 more updateAkumin Inc. Appoints Ronald J. Bienias to Serve as the Chief Restructuring OfficerAkumin Inc. announced that effective October 20, 2023, the board of directors of the Company appointed Ronald J. Bienias to serve as the company's Chief Restructuring Officer (CRO). Ronald J. Bienias, age 52, has served as a Partner & Managing Director at AlixPartners, LLP (AlixPartners") since January 2021. Mr. Bienias served as Director at AlixPartners from April 2017 through January 2021. He is a Certified Insolvency and Restructuring Advisor, and a Certified Turnaround Professional. Mr. Bienias holds an MBA from the University of Michigan's Ross School of Business.공시 • Sep 14Akumin Inc. Announces the Resignation of Rohit Navani as Chief Corporate Affairs OfficerOn September 7, 2023, Rohit Navani, the Chief Corporate Affairs Officer of Akumin Inc. (the Company), entered into a Separation Agreement and General Release (the Separation Agreement) with the Company. Under the terms of the Separation Agreement, Mr. Navani submitted to the Company a Notice of Resignation (the Notice of Resignation") pursuant to section 2.1(1) of the Employment Agreement between him and the Company dated November 15, 2017, as amended (the Employment Agreement). The Notice of Resignation became effective on September 7, 2023 (the Separation Date).분석 기사 • Aug 26These 4 Measures Indicate That Akumin (NASDAQ:AKU) Is Using Debt ExtensivelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공시 • Aug 22Akumin Inc. Receives Non-Compliance Notice from NasdaqOn August 15, 2023, Akumin Inc. (the Company) received a written notification (the Notice) from the Listing Qualifications Department of the NASDAQ Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with (a) Nasdaq Listing Rule 5550(b)(1) (the Equity Standard), pursuant to which Companies listed on the Nasdaq Capital Market (the Capital Market) are required to maintain a minimum of $2,500,000 in stockholders equity for continued listing on the Capital Market, or (b) either of the alternatives to compliance with the Equity Standard provided under Nasdaq Listing Rule 5550(b)(2) (the Market Value of Listed Securities Standard) and Nasdaq Listing Rule 5550(b)(3) (the Net Income Standard and collectively with the Market Value of Listed Securities Standard and the Equity Standard, the Continued Listing Standards). The Notice has no immediate effect on the listing of the Company's common stock on the Capital Market. Under the Nasdaq Listing Rules, the Company has a period of 45 calendar days from the date of the Notice to submit a plan to regain compliance with the Continued Listing Standards (the Plan). If the Plan is accepted, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with the Continued Listing Standards. Accordingly, the Company has until September 29, 2023 to submit the Plan to Nasdaq (the Plan Submission Date), and provided that the Plan is accepted, until February 11, 2024 to regain compliance with the Continued Listing Standards (the Compliance Date). If the Nasdaq Listing Qualifications Department does not accept the Plan, the Company will have the opportunity to appeal its decision to a Hearings Panel pursuant to Nasdaq Listing Rule 5815(a). The factors considered by the Nasdaq Listing Qualifications Department in determining whether to accept the Plan include the likelihood that the Plan will result in compliance with the Nasdaq Listing Rules, the Company's past compliance history, the reasons for the Company's current non-compliance, other corporate events that may occur within the review period, the Company's overall financial condition and its public disclosures. There can be no assurance that the Company will be able to regain compliance with the Continued Listing Standards, or will otherwise be in compliance with other Nasdaq Listing Rules. This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Company's ability to regain compliance with the Continued Listing Standards, the Company's intentions to submit the Plan by the Plan Submission Date and the Company's implementation of available options to regain compliance with the Continued Listing Standards by the Compliance Date. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including the risk that the Company may not submit the Plan by the Plan Submission Date or in the future, that the Company may not meet the Continued Listing Standards by the Compliance Date or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company's most recent annual report on Form 10-K, the Company's quarterly reports on Form 10-Q, and Current Reports on Form 8-K, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events or changes in its expectations.New Risk • Aug 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 74% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$18.6m market cap).공시 • Aug 09Akumin Inc. to Report Q2, 2023 Results on Aug 09, 2023Akumin Inc. announced that they will report Q2, 2023 results on Aug 09, 2023공시 • Jun 13Akumin Inc. Appoints Krishna Kumar as President and Chief Operating Officer of the Company, Effective as of June 16, 2023Akumin Inc. announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joining Philips, Krishna served in leadership roles across the US, Japan, China and India with Johnson & Johnson, where he was instrumental in building and scaling up many high growth businesses with innovative go-to-market strategies. Krishna is a Master of Business Administration (MBA) graduate from the Kellogg School of Management at Northwestern University, holds a post-graduate degree in management from the Indian Institute of Management and an undergraduate degree from Bangalore University in India.Reported Earnings • May 12First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.35 loss in 1Q 2022)First quarter 2023 results: US$0.39 loss per share (further deteriorated from US$0.35 loss in 1Q 2022). Revenue: US$187.6m (flat on 1Q 2022). Net loss: US$35.1m (loss widened 14% from 1Q 2022). Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.공시 • May 05Akumin Inc. to Report Q1, 2023 Results on May 10, 2023Akumin Inc. announced that they will report Q1, 2023 results on May 10, 2023Reported Earnings • Mar 17Full year 2022 earnings releasedFull year 2022 results: Revenue: US$749.6m (up 78% from FY 2021). Net loss: US$156.8m (loss widened 262% from FY 2021).Board Change • Jan 05Less than half of directors are independentFollowing Director Lawrence Sinclair's arrival on 01 January 2023, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Paul Viviano was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Nov 16Price target increased to US$3.00Up from US$2.00, the current price target is provided by 1 analyst. New target price is 152% above last closing price of US$1.19. Stock is down 41% over the past year. The company posted a net loss per share of US$0.56 last year.Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.017 loss in 3Q 2021)Third quarter 2022 results: US$0.60 loss per share (further deteriorated from US$0.017 loss in 3Q 2021). Revenue: US$186.6m (up 73% from 3Q 2021). Net loss: US$53.9m (loss widened US$52.5m from 3Q 2021). Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.Seeking Alpha • Aug 15Akumin CFO William Larkin terminated, David Kretschmer named interim CFOAkumin (NASDAQ:AKU) has implemented a transformation program with initiatives focused on its operations, growth, and capital and are intended to support the company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The company is receiving support from a globally recognized transformation specialist to help implement the program. As a part of this transformation, the company announced the termination of employment of its CFO, William Larkin, and the appointment of David Kretschmer, an experienced transformation finance executive who successfully completed other business transformations in the healthcare industry, as interim CFO, effective August 12; and the sale of certain accounts receivables by subsidiaries of the company to a third-party buyer for a purchase price of ~$30M.주주 수익률AKUM.QUS HealthcareUS 시장7D-12.8%-1.3%1.6%1Y-67.7%12.4%28.5%전체 주주 수익률 보기수익률 대 산업: AKUM.Q은 지난 1년 동안 12.4%의 수익을 기록한 US Healthcare 산업보다 저조한 성과를 냈습니다.수익률 대 시장: AKUM.Q은 지난 1년 동안 28.5%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is AKUM.Q's price volatile compared to industry and market?AKUM.Q volatilityAKUM.Q Average Weekly Movement9.5%Healthcare Industry Average Movement7.3%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.0%안정적인 주가: AKUM.Q는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: AKUM.Q의 주간 변동성은 지난 1년간 25%에서 10%로 감소했습니다.회사 소개설립직원 수CEO웹사이트2015n/aRiadh Zine Zine-El-Abidinewww.akumin.com더 보기Akumin Inc. 기초 지표 요약Akumin의 순이익과 매출은 시가총액과 어떻게 비교됩니까?AKUM.Q 기초 통계시가총액US$34.19m순이익 (TTM)-US$255.79m매출 (TTM)US$737.69m0.0x주가매출비율(P/S)-0.1x주가수익비율(P/E)AKUM.Q는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표AKUM.Q 손익계산서 (TTM)매출US$737.69m매출원가US$569.72m총이익US$167.97m기타 비용US$423.77m순이익-US$255.79m최근 보고된 실적Sep 30, 2023다음 실적 발표일해당 없음주당순이익(EPS)-2.81총이익률22.77%순이익률-34.68%부채/자본 비율-1,459.1%AKUM.Q의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/07 02:52종가2024/02/06 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Akumin Inc.는 5명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kyle McPheeATB Cormark Historical (Cormark Securities)Tania Armstrong-WhitworthCanaccord GenuityNoel AtkinsonClarus Securities Inc.2명의 분석가 더 보기
공시 • Dec 02Akumin Unveils World-First Akumin AXIS Relocatable Imaging Center with latest Siemens' PET-CT at RSNAAkumin Inc. unveiled the world's first Akumin AXIS Relocatable & Expandable Outpatient Center at the Radiological Society of North America (RSNA) meeting. This groundbreaking innovation, which is engineered to meet critical radiology and oncology requirements, was launched with a ribbon-cutting ceremony at the Akumin Booth #6158 (North Hall) on Sunday. Designed and built in the United States, Akumin AXIS is a fully equipped Outpatient Imaging or Radiation Therapy Center supporting many modalities, including PET-CTs, Linear Accelerators, and MRIs (in-progress). The spacious layout enables high-volume scanning, with 3 uptake rooms for tracer and theranostic infusions, i.e. radioligand therapies. The first unit unveiled on Sunday features Siemens Healthineers' Digital Biograph Trinion PET-CT scanner, which sets a benchmark for precision imaging and clinical outcomes. The Biograph Trinion PET-CT's unique, air-cooled design makes this solution optimal for the Akumin AXIS solution. The unveiling has sparked tremendous interest among RSNA attendees, since Akumin AXIS solves 3 key challenges faced by health systems today: large capital costs, construction time/delays, and staffing shortages. Attendees have been impressed by how Akumin AXIS enables an efficient expansion of services, improving access to high-quality care.
공시 • Feb 09+ 1 more updateAkumin Appoints Chandra Westergaard as General CounselAkumin announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. Chandra Westergaard joins Akumin from Envision Healthcare, where she most recently served as Vice President, Associate General Counsel, and Chief Litigation Counsel. Previously, she served as a Partner at Norton Rose Fulbright and Senior Counsel at Perkins Coie. Chandra also spent more than six years at DaVita as Assistant General Counsel, leading the Office of Special Counsel, and began her legal career in the healthcare group at Crowell & Moring. She received a Juris Doctorate from the Duke University School of Law and a Bachelor of Arts in Philosophy from McDaniel College.
공시 • Feb 08Akumin Files Form 15Akumin Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.
공시 • Dec 30Akumin Inc. Announces Chief Financial Officer ChangesAkumin Inc. announced that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and middle-market companies. Leveraging his financial and operational expertise, Ronald guides companies in making data-driven decisions that support restructuring strategies, financial forecasts, and cost reduction programs. Ronald has an MBA from the University of Michigan'sRoss School of Business and is a former Certified Treasury Professional.
공시 • Nov 18Nasdaq to Delist the Securities of AkuminNasdaq announced that it will delist the securities of Akumin Inc. The company’s securities were suspended on October 26, 2023, and have not traded on Nasdaq since that time.
공시 • Nov 16Akumin Inc. announced delayed 10-Q filingOn 11/14/2023, Akumin Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Dec 02Akumin Unveils World-First Akumin AXIS Relocatable Imaging Center with latest Siemens' PET-CT at RSNAAkumin Inc. unveiled the world's first Akumin AXIS Relocatable & Expandable Outpatient Center at the Radiological Society of North America (RSNA) meeting. This groundbreaking innovation, which is engineered to meet critical radiology and oncology requirements, was launched with a ribbon-cutting ceremony at the Akumin Booth #6158 (North Hall) on Sunday. Designed and built in the United States, Akumin AXIS is a fully equipped Outpatient Imaging or Radiation Therapy Center supporting many modalities, including PET-CTs, Linear Accelerators, and MRIs (in-progress). The spacious layout enables high-volume scanning, with 3 uptake rooms for tracer and theranostic infusions, i.e. radioligand therapies. The first unit unveiled on Sunday features Siemens Healthineers' Digital Biograph Trinion PET-CT scanner, which sets a benchmark for precision imaging and clinical outcomes. The Biograph Trinion PET-CT's unique, air-cooled design makes this solution optimal for the Akumin AXIS solution. The unveiling has sparked tremendous interest among RSNA attendees, since Akumin AXIS solves 3 key challenges faced by health systems today: large capital costs, construction time/delays, and staffing shortages. Attendees have been impressed by how Akumin AXIS enables an efficient expansion of services, improving access to high-quality care.
공시 • Feb 09+ 1 more updateAkumin Appoints Chandra Westergaard as General CounselAkumin announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. Chandra Westergaard joins Akumin from Envision Healthcare, where she most recently served as Vice President, Associate General Counsel, and Chief Litigation Counsel. Previously, she served as a Partner at Norton Rose Fulbright and Senior Counsel at Perkins Coie. Chandra also spent more than six years at DaVita as Assistant General Counsel, leading the Office of Special Counsel, and began her legal career in the healthcare group at Crowell & Moring. She received a Juris Doctorate from the Duke University School of Law and a Bachelor of Arts in Philosophy from McDaniel College.
공시 • Feb 08Akumin Files Form 15Akumin Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.
공시 • Dec 30Akumin Inc. Announces Chief Financial Officer ChangesAkumin Inc. announced that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and middle-market companies. Leveraging his financial and operational expertise, Ronald guides companies in making data-driven decisions that support restructuring strategies, financial forecasts, and cost reduction programs. Ronald has an MBA from the University of Michigan'sRoss School of Business and is a former Certified Treasury Professional.
공시 • Nov 18Nasdaq to Delist the Securities of AkuminNasdaq announced that it will delist the securities of Akumin Inc. The company’s securities were suspended on October 26, 2023, and have not traded on Nasdaq since that time.
공시 • Nov 16Akumin Inc. announced delayed 10-Q filingOn 11/14/2023, Akumin Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Oct 27Akumin Inc.(OTCPK:AKUM.Q) dropped from NASDAQ Composite IndexAkumin Inc. has been removed from NASDAQ Composite Index .
공시 • Oct 26Akumin Inc.(NasdaqCM:AKU) dropped from S&P TMI IndexAkumin Inc.(NasdaqCM:AKU) dropped from S&P TMI Index
공시 • Oct 24Akumin Inc. Filed for BankruptcyAkumin Inc., along with its 55 affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on October 22, 2023. The debtor listed its assets in the range of $100 million to $500 million and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Victoria Nicole Argeroplos, Beau Butler, Matthew D Cavenaugh, John Machir Stull and Jennifer F Wertz of Jackson Walker LLP and Dorsey & Whitney LLP as its legal counsels and Stikeman Elliott LLP as special Canadian counsel. The debtor also hired Leerink Partners as its investment banker, AlixPartners, LLP as its financial advisor and Epiq Corporate Restructuring LLC as noticing and claims agent. Ronald J. Bienias of AlixPartners, LLP acted as chief restructuring officer.
공시 • Oct 22+ 1 more updateAkumin Inc. Appoints Ronald J. Bienias to Serve as the Chief Restructuring OfficerAkumin Inc. announced that effective October 20, 2023, the board of directors of the Company appointed Ronald J. Bienias to serve as the company's Chief Restructuring Officer (CRO). Ronald J. Bienias, age 52, has served as a Partner & Managing Director at AlixPartners, LLP (AlixPartners") since January 2021. Mr. Bienias served as Director at AlixPartners from April 2017 through January 2021. He is a Certified Insolvency and Restructuring Advisor, and a Certified Turnaround Professional. Mr. Bienias holds an MBA from the University of Michigan's Ross School of Business.
공시 • Sep 14Akumin Inc. Announces the Resignation of Rohit Navani as Chief Corporate Affairs OfficerOn September 7, 2023, Rohit Navani, the Chief Corporate Affairs Officer of Akumin Inc. (the Company), entered into a Separation Agreement and General Release (the Separation Agreement) with the Company. Under the terms of the Separation Agreement, Mr. Navani submitted to the Company a Notice of Resignation (the Notice of Resignation") pursuant to section 2.1(1) of the Employment Agreement between him and the Company dated November 15, 2017, as amended (the Employment Agreement). The Notice of Resignation became effective on September 7, 2023 (the Separation Date).
분석 기사 • Aug 26These 4 Measures Indicate That Akumin (NASDAQ:AKU) Is Using Debt ExtensivelyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공시 • Aug 22Akumin Inc. Receives Non-Compliance Notice from NasdaqOn August 15, 2023, Akumin Inc. (the Company) received a written notification (the Notice) from the Listing Qualifications Department of the NASDAQ Stock Market LLC (Nasdaq) notifying the Company that it is not in compliance with (a) Nasdaq Listing Rule 5550(b)(1) (the Equity Standard), pursuant to which Companies listed on the Nasdaq Capital Market (the Capital Market) are required to maintain a minimum of $2,500,000 in stockholders equity for continued listing on the Capital Market, or (b) either of the alternatives to compliance with the Equity Standard provided under Nasdaq Listing Rule 5550(b)(2) (the Market Value of Listed Securities Standard) and Nasdaq Listing Rule 5550(b)(3) (the Net Income Standard and collectively with the Market Value of Listed Securities Standard and the Equity Standard, the Continued Listing Standards). The Notice has no immediate effect on the listing of the Company's common stock on the Capital Market. Under the Nasdaq Listing Rules, the Company has a period of 45 calendar days from the date of the Notice to submit a plan to regain compliance with the Continued Listing Standards (the Plan). If the Plan is accepted, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notice to evidence compliance with the Continued Listing Standards. Accordingly, the Company has until September 29, 2023 to submit the Plan to Nasdaq (the Plan Submission Date), and provided that the Plan is accepted, until February 11, 2024 to regain compliance with the Continued Listing Standards (the Compliance Date). If the Nasdaq Listing Qualifications Department does not accept the Plan, the Company will have the opportunity to appeal its decision to a Hearings Panel pursuant to Nasdaq Listing Rule 5815(a). The factors considered by the Nasdaq Listing Qualifications Department in determining whether to accept the Plan include the likelihood that the Plan will result in compliance with the Nasdaq Listing Rules, the Company's past compliance history, the reasons for the Company's current non-compliance, other corporate events that may occur within the review period, the Company's overall financial condition and its public disclosures. There can be no assurance that the Company will be able to regain compliance with the Continued Listing Standards, or will otherwise be in compliance with other Nasdaq Listing Rules. This Current Report on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the Company's ability to regain compliance with the Continued Listing Standards, the Company's intentions to submit the Plan by the Plan Submission Date and the Company's implementation of available options to regain compliance with the Continued Listing Standards by the Compliance Date. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including the risk that the Company may not submit the Plan by the Plan Submission Date or in the future, that the Company may not meet the Continued Listing Standards by the Compliance Date or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company's most recent annual report on Form 10-K, the Company's quarterly reports on Form 10-Q, and Current Reports on Form 8-K, as well as any amendments thereto reflected in subsequent filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events or changes in its expectations.
New Risk • Aug 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 74% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$18.6m market cap).
공시 • Aug 09Akumin Inc. to Report Q2, 2023 Results on Aug 09, 2023Akumin Inc. announced that they will report Q2, 2023 results on Aug 09, 2023
공시 • Jun 13Akumin Inc. Appoints Krishna Kumar as President and Chief Operating Officer of the Company, Effective as of June 16, 2023Akumin Inc. announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joining Philips, Krishna served in leadership roles across the US, Japan, China and India with Johnson & Johnson, where he was instrumental in building and scaling up many high growth businesses with innovative go-to-market strategies. Krishna is a Master of Business Administration (MBA) graduate from the Kellogg School of Management at Northwestern University, holds a post-graduate degree in management from the Indian Institute of Management and an undergraduate degree from Bangalore University in India.
Reported Earnings • May 12First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.35 loss in 1Q 2022)First quarter 2023 results: US$0.39 loss per share (further deteriorated from US$0.35 loss in 1Q 2022). Revenue: US$187.6m (flat on 1Q 2022). Net loss: US$35.1m (loss widened 14% from 1Q 2022). Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.
공시 • May 05Akumin Inc. to Report Q1, 2023 Results on May 10, 2023Akumin Inc. announced that they will report Q1, 2023 results on May 10, 2023
Reported Earnings • Mar 17Full year 2022 earnings releasedFull year 2022 results: Revenue: US$749.6m (up 78% from FY 2021). Net loss: US$156.8m (loss widened 262% from FY 2021).
Board Change • Jan 05Less than half of directors are independentFollowing Director Lawrence Sinclair's arrival on 01 January 2023, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Paul Viviano was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Nov 16Price target increased to US$3.00Up from US$2.00, the current price target is provided by 1 analyst. New target price is 152% above last closing price of US$1.19. Stock is down 41% over the past year. The company posted a net loss per share of US$0.56 last year.
Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.017 loss in 3Q 2021)Third quarter 2022 results: US$0.60 loss per share (further deteriorated from US$0.017 loss in 3Q 2021). Revenue: US$186.6m (up 73% from 3Q 2021). Net loss: US$53.9m (loss widened US$52.5m from 3Q 2021). Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Seeking Alpha • Aug 15Akumin CFO William Larkin terminated, David Kretschmer named interim CFOAkumin (NASDAQ:AKU) has implemented a transformation program with initiatives focused on its operations, growth, and capital and are intended to support the company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The company is receiving support from a globally recognized transformation specialist to help implement the program. As a part of this transformation, the company announced the termination of employment of its CFO, William Larkin, and the appointment of David Kretschmer, an experienced transformation finance executive who successfully completed other business transformations in the healthcare industry, as interim CFO, effective August 12; and the sale of certain accounts receivables by subsidiaries of the company to a third-party buyer for a purchase price of ~$30M.
